About InLight Bio

What we cover

New biomedical science: briefs on recent papers and preprints in organoids, disease models, AI drug design, tumor immunology and cell therapy, autoimmunity, vaccines, antibody engineering, nucleic-acid medicines and precision oncology, each written from the original paper with a DOI link.

Global biopharma licensing: out-licensing deals, NewCo formation, M&A and the clinical data that drives asset value, with deep coverage of China-origin programs. Readers are investors, pharma business-development teams and NewCo founders who need a fast, sourced view of licensable assets and deals.

Each brief gives the headline terms with upfront and milestone payments separated, a short summary of the science and the deal logic, and a link to the original announcement or trade-press source.

Editorial

Jing Huang, PhD, Editor. Writes and edits the science briefs and deal briefs on this site and is responsible for corrections.

Follow InLight Bio on LinkedIn. Corrections: contact@inlightbio.com.

Editorial principles

• Sources. Every item links to its original source. Items based only on a press release or secondary coverage say so.
• Deal amounts. Upfront and milestones are listed separately, as publicly disclosed.
• Accuracy. Summaries add no facts or numbers beyond the original source.
• Illustrations. Images on deal items and science covers are AI-generated illustrations, not data or journal figures.
• Conflicts. We also run a NewCo partnering business. If a company we cover is a client or counterparty, we disclose it at the top of the item. Sponsored content, if any, is labeled “Supported by …”.
• Corrections. Send corrections to contact@inlightbio.com; we mark corrections on the item.

Publisher

InLight Bio publishes the science and deal briefs on this site and runs the reports and NewCo partnering services described on the Services page.

Contact